Btg Share Discussion Threads

[ugandalad] 15/11/2017 08:47

Morningstar on 14th published interview with Barnett of Invesco. Apart from an interesting observation on oil he made this comment

Pharmaceuticals are another international area Barnett is bullish about. He benefits here from the ability to select non-UK-listed stocks and holds Swiss pharma Roche (RO) as well as many US firms. In the UK, he has big positions in AstraZeneca (AZN) and BTG (BTG).
Demographic trends in both developed and emerging markets – ageing populations – are “well established” and “prospects for pipelines are better than we have seen for some time”, he says. In the developing world, “consumers are demanding better standards of healthcare and western drugs and the companies that can benefit from that are the companies that I own”.

[cyman] 14/11/2017 23:40

Last 5 posts from respected long term holders whom I have known for a while probably most sensible posts of the day. My only kick is that btg has had potential for the last 15 years but when are we going to see some heady days? I entered around the 250 mark with a few buys in 300s keen to see the £11 that we have talked about so often or the £21 that we used to talk about

[ugandalad] 14/11/2017 12:15

K1P2 I agree this has gone from a snake oil producer with a heady pe of 58 (2013) to a multiproduct company as new treatments have come on stream almost doubling my shares value so its done me well. Think the market is now too pessimistic on its price given the problems with Varithena knocked the PE down when it first came out that there was no insurance claim code. The same issue is knocking the price even though another step forward has been achieved. Waiting a year for the impact on this product is well within my boundaries particularly as the business is profitable,cash generative with cash balances to meet its R&D needs. The loss has been covered by first half profits. I'll await with interest (and hope) for the next 6 months results.

[king1pin2] 14/11/2017 12:15

Well he may be right but who knows with shares. V is a very good product that works so that what matters in my book. BTG seems to be in a good space and while they have made mistakes thats life but looking forward they seem to be a good bet.

[king1pin2] 14/11/2017 11:47

Hmm well its a share that i have held for many years so its been one of my very best investments so cant say that i am not happy with the performance apart from a buy at around 7.50.... Still keep the faith .

[semper vigilans] 14/11/2017 11:21

This empire building has got to stop. Expansion only designed to cover up mistakes.
Needs a wealthy US predator now.

[cockneytrader] 14/11/2017 11:18

No, don't short.

But this will probably drift down now, as H2 is more quiet and there is no news expected for a while.

That said, there could be an acquisition. The credit facility was extended to £300 million.

The long term story is still intact and we have a new cfo.

[gregmorg] 14/11/2017 11:11

heavens forbid- could that be possible!!

[king1pin2] 14/11/2017 10:26

Just listining to the webcast , As i thought Inverstment is now minimum and they think that very little money is required to drive sales.

[king1pin2] 14/11/2017 09:29

ah yes well thats another matter, Volume sales may help with that but its a wait and see as you say.

[cockneytrader] 14/11/2017 09:17

It looks as if The codes don't fully cover treatment costs. We will find out more soon.

[king1pin2] 14/11/2017 09:13

Well i do undestand cost of sales and that when you are pushing a product it can cost lots of money but thats when you are pushing for market share.
The pull side is less ecpensive when demand from the market for a product that works and is getting good feedback lessins the need for spending on promoting the product.
All just my view but was not surprised that we have encountered insurance problems with V. But the insurance code will help matters.

[cockneytrader] 14/11/2017 09:03

With respect, but I am not sure you understand cost of sales.

Revenue is all well and good, but it's profit that counts!

[king1pin2] 14/11/2017 08:50

Cant see that being honest cos all of the cost of bringing it to market has now been spent so even IF its not a blockbuster as first thought it will still bring in revenuue for the company.

[semper vigilans] 14/11/2017 08:32

FD replacement had to be an appointment from inside to save embarrassment.

[cockneytrader] 14/11/2017 08:28

But, I hope to be proved wrong.

[cockneytrader] 14/11/2017 08:27

Because writing it off would save a small fortune going forward.

[king1pin2] 14/11/2017 08:15

I dont have any idea why you think Varithena would be written off, The treatment works well and now that the codes are sorted should start to gain momentum.
The share price has gained because all the bad news was in the share price before todays news.
I think the results are solid so am happy to be in around this level.
I know two that have had the treatment and both are very happy with the resuls.

[spyder] 14/11/2017 08:01

So, it looks like the Wellstat debacle was Rolf's fault? Bad timing for him to go if that is not the case.
The CEO will effectively be on her own at the Q&A, I hope the analysts don't give her too easy a time of it.
I am still in shock over Wellstat, it was a cataclysmic error by someone at BTG.

[fhmktg] 14/11/2017 07:56

I wonder to what extent Rolf is carrying the can for his executive responsibilities for:1 His management of currency hedging2 Due diligence in relation to the the trading manipulation of the beads business prior to the takeover of Biocompatibles 3 The decision to put cost saving over contractual liabilities for Wellstat.Each of these were significant on its own, but together have cost over $100 million in cash and impairment.